ype 1 Diabetes • Sickle Cell Disease • Congenital Heart Disease • Rheumatic Heart Disease • Asthma
Checking Date & Time
Reading File
Asking for Preferences
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
I now have comprehensive content from authoritative sources. Let me compile the full clinical overviews.
Pediatric Non-Communicable Diseases (NCDs): Clinical Overviews
1. Type 1 Diabetes Mellitus (T1DM)
Epidemiology
T1DM is the most common pediatric endocrine disorder, with a prevalence of approximately 1 in 400 children. Its incidence increased by 21% between 2001 and 2009. It most commonly afflicts children, adolescents, and young adults. Notably, up to 34% of children with new-onset T1DM present in diabetic ketoacidosis (DKA), and DKA is the leading cause of mortality in patients with diabetes under 24 years of age — with cerebral edema being the leading cause of death within DKA.
— Tintinalli's Emergency Medicine, p. 1013
Pathophysiology
T1DM results from autoimmune-mediated destruction of pancreatic β cells, triggered by viral or environmental stimuli in genetically predisposed individuals. The result is absolute insulin deficiency:
- Without basal insulin secretion, lipolysis, proteolysis, and glycogenolysis are unopposed
- Elevated counterregulatory hormones (catecholamines, cortisol, growth hormone, glucagon) drive glycogenolysis, gluconeogenesis, and ketogenesis
- Serum glucose exceeds the renal threshold → osmotic diuresis → dehydration + electrolyte loss
- Free fatty acid overabundance → hepatic conversion to acetoacetate and β-hydroxybutyrate → wide anion gap metabolic acidosis
— Lippincott Illustrated Reviews: Pharmacology, p. 795; Tintinalli's Emergency Medicine, p. 1013
Clinical Features
Classic triad: polyuria, polydipsia, polyphagia + weight loss, secondary enuresis, vague abdominal pain, visual changes, genital candidiasis.
Diagnosis
| Test | Threshold |
|---|---|
| Fasting plasma glucose | ≥ 126 mg/dL |
| 2-hour postprandial glucose | ≥ 200 mg/dL |
| HbA1c | ≥ 6.5% |
| Prediabetes (fasting glucose) | 100–125 mg/dL |
Autoantibodies (anti-GAD, anti-islet cell) help distinguish T1DM from T2DM in children.
Management
- Insulin replacement is mandatory — physiologically based intensive regimens using basal-bolus insulin or continuous subcutaneous insulin infusion (CSII/pump)
- Glycemic targets: fasting glucose 80–130 mg/dL; postprandial < 180 mg/dL; HbA1c < 7.5% in most pediatric patients
- Home blood glucose monitoring and continuous glucose monitors (CGMs) are standard
- DKA management: IV fluid resuscitation, insulin infusion, potassium replacement, careful monitoring for cerebral edema
2. Sickle Cell Disease (SCD)
Epidemiology
SCD is the most common familial hemolytic anemia. In the United States, ~8% of people of African descent are heterozygous HbS carriers; approximately 1 in 600 have sickle cell anemia. The HbS allele is prevalent in areas historically endemic for P. falciparum malaria (equatorial Africa, parts of India, the Middle East, southern Europe).
— Robbins & Kumar Basic Pathology, p. [Sickle Cell Anemia section]
Pathophysiology
SCD is caused by a single amino acid substitution in β-globin: valine replaces glutamate at position 6. This creates HbS, which on deoxygenation undergoes conformational change and polymerizes, distorting red cells into the characteristic sickle shape.
Key factors driving sickling:
- HbS concentration — higher levels increase polymerization risk
- Presence of other hemoglobins — HbF and HbA inhibit polymerization; HbF is protective in neonates until ~5–6 months of age
- Intracellular dehydration — raises MCHC, facilitating sickling
Consequences:
- Sickling → calcium influx → K⁺ and H₂O loss → irreversibly sickled cells → hemolysis and chronic hemolytic anemia
- Microvascular occlusion → vaso-occlusive crises: bone pain, acute chest syndrome, stroke, splenic sequestration, priapism
- Functional asplenia → vulnerability to encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae)
— Robbins & Kumar Basic Pathology; Robbins, Cotran & Kumar Pathologic Basis of Disease
Clinical Features & Complications
| System | Manifestation |
|---|---|
| Hematologic | Chronic hemolytic anemia (Hb 6–9 g/dL), aplastic crisis (parvovirus B19) |
| Musculoskeletal | Vaso-occlusive pain crises, avascular necrosis |
| Pulmonary | Acute chest syndrome (fever, chest pain, new infiltrate, hypoxia) |
| Neurologic | Ischemic stroke (especially in children 2–10 years) |
| Splenic | Acute splenic sequestration, functional asplenia |
| Renal | Hyposthenuria, hematuria, papillary necrosis |
| Ophthalmologic | Proliferative sickle retinopathy |
Management
- Hydroxyurea — increases HbF production, reduces sickling and vaso-occlusive events; first-line disease-modifying therapy
- Prophylactic penicillin from 2 months of age due to functional asplenia
- Pneumococcal, meningococcal, and H. influenzae vaccination
- Chronic transfusion therapy or exchange transfusion for stroke prevention/treatment
- Pain crises: IV fluids, analgesia (NSAIDs + opioids), oxygen
- Curative: allogeneic hematopoietic stem cell transplantation (HLA-matched sibling)
3. Congenital Heart Disease (CHD)
Epidemiology
CHD affects approximately 8 in 1,000 live births and is the most common category of birth defects. It encompasses a spectrum from simple defects (small VSDs) to complex cyanotic lesions.
Classification
Acyanotic CHD (left-to-right shunts):
| Defect | Key Features |
|---|---|
| VSD (most common CHD) | Holosystolic murmur, pulmonary overcirculation; risk of Eisenmenger syndrome |
| ASD | Fixed split S₂, pulmonary flow murmur; often asymptomatic in childhood |
| PDA | Continuous "machinery" murmur, bounding pulses |
| Coarctation of the aorta | Upper extremity hypertension, femoral pulse delay |
Cyanotic CHD (right-to-left shunts):
| Defect | Key Features |
|---|---|
| Tetralogy of Fallot (most common cyanotic CHD, ~5% of all CHD) | VSD + RV outflow obstruction + overriding aorta + RVH; "Tet spells," boot-shaped heart on CXR |
| Transposition of the Great Arteries | Parallel circulations; ductal-dependent; urgent prostaglandin E₁ |
| Truncus arteriosus | Single great artery, mixing, early cyanosis + heart failure |
| HLHS (Hypoplastic Left Heart Syndrome) | Univentricular; requires staged surgical palliation (Norwood → Glenn → Fontan) |
— Tintinalli's Emergency Medicine; Robbins & Kumar Basic Pathology
Pathophysiology
- Left-to-right shunts cause pulmonary overcirculation → pulmonary hypertension → if untreated, eventual reversal (Eisenmenger syndrome, cyanosis)
- Right-to-left shunts (cyanotic CHD) cause hypoxemia, polycythemia, clubbing
Management Principles
- Prostaglandin E₁ (PGE₁) to maintain ductal patency in ductal-dependent lesions
- Surgical/interventional repair — timing varies by defect:
- Arterial switch for TGA (neonatal period)
- TOF complete repair ~6 months
- Staged Fontan palliation for single-ventricle physiology
- Subacute bacterial endocarditis (SBE) prophylaxis where indicated
- Diuretics for heart failure; weight-based dosing must be adjusted regularly as child grows
- Long-term cardiology follow-up; many children will require re-intervention
4. Rheumatic Heart Disease (RHD)
Epidemiology
RHD remains the most important form of acquired heart disease in children and young adults in low- and middle-income countries (LMICs). Its incidence has declined markedly in high-income countries with improved socioeconomic conditions and rapid streptococcal treatment, but it remains a major burden globally.
Pathogenesis
RHD is the cardiac manifestation of acute rheumatic fever (ARF), itself a consequence of pharyngeal infection by Group A β-hemolytic Streptococcus (GAS). The mechanism is molecular mimicry: streptococcal antigens (M protein epitopes) cross-react with cardiac proteins, triggering an autoimmune response that causes:
- Pancarditis (endocarditis, myocarditis, pericarditis)
- Formation of Aschoff bodies — pathognomonic granulomas with Anitschkow cells (activated macrophages with caterpillar chromatin)
Repeated episodes of ARF progressively scar and deform the valves → chronic RHD
— Robbins & Kumar Basic Pathology, p. 366
Valvular Involvement
| Valve | Lesion |
|---|---|
| Mitral (most common) | Stenosis > regurgitation; commissural fusion, chordal shortening |
| Aortic | Stenosis/regurgitation; thickening and distortion of cusps |
| Tricuspid | Less commonly affected |
Mitral stenosis caused by RHD is essentially the only cause of acquired mitral stenosis — a key clinical distinguishing feature.
Diagnosis — Jones Criteria (Modified 2015)
Major criteria: Carditis (clinical/subclinical), polyarthritis, chorea, erythema marginatum, subcutaneous nodules
Minor criteria: Fever, elevated ESR/CRP, prolonged PR interval
Plus: Evidence of preceding GAS infection (positive throat culture, rapid antigen test, rising ASOT, or recent scarlet fever)
Diagnosis = 2 major OR 1 major + 2 minor criteria
Minor criteria: Fever, elevated ESR/CRP, prolonged PR interval
Plus: Evidence of preceding GAS infection (positive throat culture, rapid antigen test, rising ASOT, or recent scarlet fever)
Diagnosis = 2 major OR 1 major + 2 minor criteria
Management
Acute ARF:
- Benzathine penicillin G (or amoxicillin) to eradicate GAS
- Anti-inflammatory therapy: aspirin (arthritis), corticosteroids (severe carditis)
- Bed rest during acute phase
Secondary Prophylaxis (critical to prevent recurrence):
- Benzathine penicillin G 1.2 million units IM every 3–4 weeks (preferred)
- Duration: minimum 10 years or until age 21 (longer if significant valvular disease persists)
- This is the single most important intervention to prevent progressive valve damage
Valve disease management:
- Medical: diuretics, afterload reduction, anticoagulation for mitral stenosis with AF
- Surgical: mitral valvotomy, valve repair, or replacement
5. Asthma
Epidemiology
Asthma is the most common chronic disease of childhood. It is a leading cause of pediatric hospitalizations and school absenteeism. One-third of pediatric deaths from asthma occur in children who previously had only mild disease.
Pathophysiology
Three core processes:
- Airway inflammation — central to pathophysiology; involves complex interplay of cytokines, chemokines, IgE, lymphocytes, mast cells, and eosinophils
- Bronchospasm — driven by mast cell degranulation and smooth muscle contraction
- Airway remodeling — subepithelial fibrosis, smooth muscle hypertrophy, mucous gland hyperplasia with chronic disease
Atopic (allergic) asthma — most common form; Th2-mediated IgE response to environmental allergens (house dust mite, pet dander, pollen). Allergen binding to IgE on mast cells → degranulation → histamine, leukotrienes, prostaglandins → bronchoconstriction and airway edema.
— Tintinalli's Emergency Medicine; Robbins, Cotran & Kumar Pathologic Basis of Disease
Clinical Features
- Episodic wheeze, cough (particularly nocturnal), chest tightness, dyspnea
- Expiratory wheeze on auscultation; prolonged expiratory phase
- Hyperresonance, accessory muscle use in severe attacks
Severity Classification (GINA-based)
| Step | Control Level | Symptoms |
|---|---|---|
| Intermittent | Controlled | < 2 days/week |
| Mild persistent | Partly controlled | > 2 days/week but not daily |
| Moderate persistent | Uncontrolled | Daily symptoms |
| Severe persistent | Uncontrolled | Continuous, frequent nocturnal |
Management — Stepwise Approach
| Agent | Role |
|---|---|
| SABA (salbutamol/albuterol) | Reliever for acute bronchospasm |
| Inhaled corticosteroids (ICS) | First-line controller; reduces inflammation |
| LABA (formoterol, salmeterol) | Add-on to ICS for moderate–severe persistent (not monotherapy in children) |
| Leukotriene receptor antagonists (montelukast) | Alternative/add-on controller |
| Systemic corticosteroids | Acute exacerbations; short courses |
| Magnesium sulfate IV | Severe/refractory exacerbations |
| BiPAP | Near-fatal asthma; may avert intubation |
| Ketamine | Preferred induction agent for intubation (bronchodilatory + sympathomimetic) |
Methylxanthines (theophylline) are no longer recommended due to narrow therapeutic window and adverse effect profile.
— Tintinalli's Emergency Medicine, p. 2493
Comparative Summary
| Feature | T1DM | SCD | CHD | RHD | Asthma |
|---|---|---|---|---|---|
| Primary mechanism | Autoimmune β-cell destruction | Hemoglobin mutation (HbS) | Embryological structural defect | Post-streptococcal autoimmunity | Allergic/inflammatory airway disease |
| Key complication | DKA, hypoglycemia, microvascular disease | Vaso-occlusive crisis, ACS, stroke | Heart failure, cyanosis, Eisenmenger | Mitral stenosis, heart failure | Respiratory failure, status asthmaticus |
| Disease-modifying therapy | Insulin | Hydroxyurea | Surgery | Penicillin prophylaxis | ICS |
| Prevention | Screening autoantibodies | Newborn screening, penicillin prophylaxis | Fetal echocardiography | Rapid treatment of strep pharyngitis | Allergen avoidance, early ICS |
| Cure | Islet/pancreas transplant | HSCT | Surgical repair (many defects) | Valve surgery (end-stage) | None (remission possible) |
Sources:
- Lippincott Illustrated Reviews: Pharmacology — T1DM pathophysiology and treatment
- Tintinalli's Emergency Medicine — Pediatric DKA, CHD, asthma management
- Robbins & Kumar Basic Pathology — Sickle cell disease and rheumatic valvular disease pathology
- Robbins, Cotran & Kumar Pathologic Basis of Disease — SCD molecular pathogenesis, asthma pathophysiology
- Goldman-Cecil Medicine — RHD management guidelines
This is a shared conversation. Sign in to Orris to start your own chat.